Items Tagged ‘HRPC’

February 23rd, 2015

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients


The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported in The Lancet Oncology and clear the way for a new treatment option for men with hormone refractory prostate cancer (HRPC).1 Prostate cancer is a […]

View full entry

Tags: abiraterone acetate, cancer, HRPC, Metastatic Stage IV (D) Prostate Cancer, new treatment option, News, prednisone, prostate, Prostate Cancer, Refactory/Recurrent Prostate Cancer, zytiga